

**EUnetHTA WP5
Relative Effectiveness Assessment (REA) of Pharmaceuticals**

**Public consultation of WP5 Joint Action 1: HTA Core Model for Rapid
Relative Effectiveness Assessment of Pharmaceuticals
- List with commentators -**



**Public consultation of WP5 HTA Core Model for Rapid Relative Effectiveness
Assessment of Pharmaceuticals**

The draft HTA Core Model for Rapid Relative Effectiveness Assessment of Pharmaceutical under production by Work Package 5 Joint Action 1 was open for public consultation from 1 October 2012 to 30 November 2012.

Objective of the Model

It is the objective of work package 5 (WP5) to develop HTA tools and methods for relative effectiveness assessment (REA) of pharmaceuticals. For this purpose the HTA Core Model was adapted into a version that specifically aims at REA of pharmaceuticals: the HTA Core Model for Rapid Relative Effectiveness Assessment of Pharmaceuticals.

List with commentators

The list below provides the contact information of all the organisations that properly submitted contributions as part of the public consultation.

	Comments provided by	Abbreviation
1.	Association of the European Self-Medication Industry George Yiangou (g.yiangou@aesgp.eu) 7 avenue de Tervuren, 1040 Brussels, Belgium Tel: +3227355130	AESGP
2.	EuropaBio Aleksandra Krygiel-Nael (a.krygiel@europabio.org) Avenue de l'Armée 6, 1040 Brussels Belgium Tel : +32 2 739 11 82	EuropaBio
3.	European Federation of Pharmaceutical Industries and Associations Edith Frénoy (edith.frenoy@efpia.eu) Rue du Trone 108, 1050 Bruxelles, Belgium Tel: +3226262548	EFPIA
4.	Novartis Jennifer Cain Birkmose (Jennifer.cain@novartis.com) Novartis Campus, Forum 1, CH 4051, Switzerland Tel: +41797857397	Novartis
5.	Eli Lilly and Company Franz Pichler (fpichler@network.lilly.com), Jim Murray, David Grainger Lilly UK, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK Tel: +447711389672	Eli Lilly and
6.	Healthcare Improvement Scotland Heather McIntosh (heather.mcintosh1@nhs.net) Delta House, 50 West Nile St, Glasgow, G1 2PN, Scotland, UK Tel: +441412256980	HIS

**EUnetHTA WP5
Relative Effectiveness Assessment (REA) of Pharmaceuticals**

**Public consultation of WP5 Joint Action 1: HTA Core Model for Rapid
Relative Effectiveness Assessment of Pharmaceuticals
- List with commentators -**



**Final version of HTA Core Model for Rapid Relative Effectiveness Assessment of
Pharmaceutical**

The final version of the model will be published on the EUnetHTA website by the end of February 2012.

Contact information

CVZ (College voor zorgverzekeringen)
Sarah Kleijnen, email: skleijnen@cvz.nl